Citadel Advisors’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $323K | Buy |
+19,900
| New | +$352K | ﹤0.01% | 10313 |
|
|
2025
Q2 | – | Sell |
-700
| Closed | -$6.25K | – | 15035 |
|
|
2025
Q1 | $6.25K | Buy |
700
+100
| +17% | +$931 | ﹤0.01% | 13767 |
|
|
2024
Q4 | $5.65K | Buy |
600
+400
| +200% | +$3.64K | ﹤0.01% | 13847 |
|
|
2024
Q3 | $1.61K | Sell |
200
-13,700
| -99% | -$119K | ﹤0.01% | 13828 |
|
|
2024
Q2 | $118K | Buy |
13,900
+12,500
| +893% | +$113K | ﹤0.01% | 10679 |
|
|
2024
Q1 | $12.6K | Sell |
1,400
-3,100
| -69% | -$28.7K | ﹤0.01% | 13357 |
|
|
2023
Q4 | $50.6K | Sell |
4,500
-2,500
| -36% | -$25.2K | ﹤0.01% | 11770 |
|
|
2023
Q3 | $60.4K | Sell |
7,000
-3,800
| -35% | -$36.7K | ﹤0.01% | 11522 |
|
|
2023
Q2 | $112K | Buy |
10,800
+2,300
| +27% | +$25.4K | ﹤0.01% | 10760 |
|
|
2023
Q1 | $92.2K | Sell |
8,500
-40,100
| -83% | -$424K | ﹤0.01% | 11380 |
|
|
2022
Q4 | $545K | Buy |
48,600
+30,600
| +170% | +$322K | ﹤0.01% | 8057 |
|
|
2022
Q3 | $183K | Buy |
18,000
+8,000
| +80% | +$75K | ﹤0.01% | 10493 |
|
|
2022
Q2 | $91K | Sell |
10,000
-12,200
| -55% | -$112K | ﹤0.01% | 11501 |
|
|
2022
Q1 | $212K | Sell |
22,200
-9,400
| -30% | -$92.1K | ﹤0.01% | 11393 |
|
|
2021
Q4 | $349K | Sell |
31,600
-287,200
| -90% | -$2.5M | ﹤0.01% | 10579 |
|
|
2021
Q3 | $2.36M | Buy |
+318,800
| New | +$3.57M | ﹤0.01% | 5937 |
|
|
2021
Q2 | – | Sell |
-10,800
| Closed | -$220K | – | 14417 |
|
|
2021
Q1 | $220K | Buy |
+10,800
| New | +$205K | ﹤0.01% | 11512 |
|
|
2020
Q1 | – | Sell |
-8,200
| Closed | -$212K | – | 10165 |
|
|
2019
Q4 | $212K | Buy |
+8,200
| New | +$159K | ﹤0.01% | 8090 |
|
|
2019
Q3 | – | Sell |
-19,300
| Closed | -$315K | – | 9742 |
|
|
2019
Q2 | $315K | Buy |
+19,300
| New | +$391K | ﹤0.01% | 7517 |
|
|
2018
Q4 | – | Sell |
-6,800
| Closed | -$222K | – | 9738 |
|
|
2018
Q3 | $222K | Buy |
+6,800
| New | +$185K | ﹤0.01% | 8050 |
|
|
2016
Q1 | – | Sell |
-4,900
| Closed | -$80K | – | 7916 |
|
|
2015
Q4 | $80K | Buy |
+4,900
| New | +$77.8K | ﹤0.01% | 6914 |
|
|
2015
Q3 | – | Sell |
-5,700
| Closed | -$74K | – | 9225 |
|
|
2015
Q2 | $74K | Buy |
5,700
+1,000
| +21% | +$15.5K | ﹤0.01% | 7368 |
|
|
2015
Q1 | $82K | Buy |
4,700
+3,000
| +176% | +$55K | ﹤0.01% | 7005 |
|
|
2014
Q4 | $25K | Sell |
1,700
-1,100
| -39% | -$19.2K | ﹤0.01% | 7657 |
|
|
2014
Q3 | $65K | Buy |
2,800
+500
| +22% | +$14.5K | ﹤0.01% | 6731 |
|
|
2014
Q2 | $73K | Buy |
+2,300
| New | +$69.2K | ﹤0.01% | 6472 |
|
Other funds holding TBPH
MAP
WAM
NM
ICM
VCM
Citadel Advisors's TBPH Position: Q1 2026 in Review
Citadel Advisors reduced its Theravance Biopharma (TBPH) stake by 63% in Q1 2026, selling an estimated $2.65M and leaving 86,091 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #6880.
Citadel Advisors first reported a position in TBPH in Q2 2014 and has held it in 33 quarters since. The position peaked at $5.35M in Q2 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.
- Citadel Advisors held 86,091 shares of Theravance Biopharma worth $1.4M as of Q1 2026.
- Citadel Advisors sold 149,609 Theravance Biopharma shares in Q1 2026, an estimated $2.65M.
- Theravance Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6880 holding.
- Citadel Advisors first reported a position in Theravance Biopharma in Q2 2014 and has held it in 33 quarters since.
- Citadel Advisors's Theravance Biopharma position peaked at $5.35M in Q2 2025.
- 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.